SciTech Development

SciTech Development Company Overview

Earle Holsapple, SciTech President, describes the company's patented ST-001 nanoFenretinide technology (nanoparticle sized fenretinide) and the investment opportunity. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | (313) 263-4887 |

SciTech Presentation & Interview at NIBA Investment Conference in New York City

Earle Holsapple introduces SciTech's patented ST-001 nanoFenretinide technology (nanoparticle sized fenretinide in a phospholipid matrix) to the investment banking community.

SciTech Development Enabling Proven Cancer Therapies

ST-001 nanoFenretinide, a nanoparticle fenretinide formulation, offers increased hope for cancer sufferers. For Crowdfunding Cancer-Fighting Donations, visit

SciTech Development: The Company, The Technology and The Investment Opportunity

SciTech presentation including company overview, patented technology, lead drug ST-001 nanoFenretinide fenretinide, addressable markets, competition, key personnel, advisory board, drug product characteristics, fenretinide history, and drug mechanism of action (MOA).

No Audio

SciTech at China BioMed Innovation and Investment Conference (CBIIC) September 2019 in Suzhou, China

Earle Holsapple introduces the company's patented ST-001 nanoFenretinide fenretinide technology to the Chinese investment, biotech and pharmaceutical industry at CBIIC. 

No Audio

Fenretinide ST-001 NanoFenretinde Drug Mechanism of Action (MOA)

The mechanism of action for SciTech's patented, lead cancer drug ST-001 nanoFenretinide (nanoparticle sized fenretinide in a phospholipid matrix).


Twitter - #SciTechUSA - SciTech Development
Pinterest - SciTech Development

For investment and partnering opportunities contact:

Earle Holsapple  | 

© 2017-2020 SciTech Development LLC